The goal of the Leadership and Administration Core is to ensure that translational goals of the POCRC are met and that resources are used effectively. The Leadership Core is responsible for ongoing evaluation of scientific and translational progress of all projects. If progress is not sufficient, the Executive Committee comprised of Dr. Nicole Urban, Principal Investigator, and co-principal investigators, Drs. Mary (Nora) Disis, Charles Drescher, Beth Karlan, Steve Collins, and Martin (Mac) Cheever, will take necessary action. The Executive Committee is also responsible for ensuring that cores meet the needs of projects without redundancy or confiict, providing scientific leadership, facilitafing Inter-SPORE communication, coordinafing collaborations, integrating POCRC and CCSG activities, and allocating SPORE resources. The,Leadership Core will be responsible for coordinating SPORE activities and assuring communication between the cores, projects and committees. Committees within the Leadership Core will include representation from members ofthe Patient Advocate Group to make certain that the POCRC constanfiy works towards achieving its translational goals and meeting the needs ofthe patient. The Leadership Core will provide overall guidance for the translational activities ofthe SPORE, building on established interdisciplinary collaborations. It will promote, oversee, and evaluate active interaction between the cores and the projects. Through the advisory boards and committees, the Leadership Core will provide the following functions: 1) overall management and coordination ofthe SPORE;2) meet the scientific advisory needs of the individual research projects;3) oversee, plan, and evaluate SPORE acfivifies including inter? SPORE activities;4) promote, oversee, and evaluate interaction of cores and projects;5) encourage, select, and guide developmental projects;6) provide mentoring and career development;7) manage, distribute, and re-allocate SPORE funds and other resources as appropriate;8) oversee IRB activity;9) ensure that scientific objectives can ultimately be translated to patient care;10) initiate new activities in response to important translational research opportunities. To address the needs of the projects and the cores, experts in ovarian cancer, translational research, early detection/screening, epidemiology, genomics, immunology, statistical methods, informatics, and pathology have been identified and recruited to serve in the Leadership Core. Senior leaders with relevant expertise will interact with each other on substantive committees as well as provide mentorship to POCRC investigators who are experts in their own fields but less acquainted with other disciplines that are critical to career development in ovarian cancer translational research and the overall success ofthe POCR(Z;.
The goal of this ovarian SPORE is to demonstrate better strategies for 1) screening high-risk women using novel serum markers and state-of-the-art imaging without the need for another large trial, by integrating our Phase I trial results with reports from ongoing Phase III efficacy trials;2) selecting women for neoadjuvant therapy by testing their blood for a resectability signature;and 3) immunizing women against their own tumors to prevent recurrence. Success in one or more of these efforts will significantly reduce the burden of ovarian cancer.
|Hooda, Jagmohan; Novak, Marian; Salomon, Matthew P et al. (2018) Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res :|
|Kondrashova, Olga; Topp, Monique; Nesic, Ksenija et al. (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970|
|Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874|
|Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273|
|Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049|
|Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34|
|Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284|
|Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485|
|Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:|
|Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998|
Showing the most recent 10 out of 187 publications